Its side effects are related to 17-alpha hydroxylase inhibition leading to a decrease in cortisol production and consequent increase in ACTH release, mineralocorticoid production, and ensuing hypokalemia, which itself is a risk factor for rhabdomyolysis [16, 17]. This evidence concerns the gene POMC and rhabdomyolysis.